Skip to content

莱博科

US · LH #790 按市值排名 上市于 1970
317.95 -7.12 -2.19%
实时 - 追踪5344个代码 - 心跳于554秒前 · 2026-10-16 17:21

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了6家。
  • 机构持股总比例下降了0.3个百分点。

机构持股

机构持股比例
103.06% -0.33pp
机构数量
1,248 -6
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向一致

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund90.30%
Hedge Fund4.76%
Public Company3.59%
Government Pension Fund1.41%
Private Company1.07%
Sovereign Wealth Fund1.05%
Individual/Insider0.39%
Family Office/Trust0.35%
Insurance Company0.27%

主要股东 截至 2026-06-30

BlackRock 8.11% · 6.57M 股
Vanguard Capital Management, LLC 7.18% · 5.82M 股
Victory Capital Management Inc. 5.96% · 4.84M 股
State Street Global Advisors 4.82% · 3.91M 股
Vanguard Portfolio Management, LLC 4.54% · 3.68M 股
Boston Partners Global Investors, Inc. 3.76% · 3.05M 股
Allspring Global Investments, LLC 2.76% · 2.24M 股
Geode Capital Management, LLC 2.70% · 2.19M 股
Select Equity Group, L.P. 2.44% · 1.98M 股
FMR 2.26% · 1.83M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 17次买入 · 33次卖出

姓名职务持股比例
Adam Schechter Chairperson & CEO 0.13%
Glenn Eisenberg Chief Financial Officer 0.05%
Brian Caveney EVP, President of Early Development Research Laboratories & Chief Medical Officer 0.05%
Lance Berberian Executive VP and Chief Information & Technology Officer 0.02%
Peter Neupert Independent Director 0.02%
Garheng Albert Kong Lead Independent Director 0.02%
Mark Schroeder Executive VP, President of Diagnostics Laboratories & COO 0.02%
Amy Summy Chief Marketing Officer 0.01%
Kerrii Anderson Independent Director 0.01%
Bryan Vaughn Executive Vice President of Diagnostics 0.01%

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-08-31 Brian Caveney EVP, President of Early Development Research Laboratories & Chief Medical Officer Other Derivative Acquisition +3,000 --
2026-08-31 Akinbolade Oyegunwa Executive VP and Chief Information & Technology Officer Other Derivative Acquisition +750 --
2026-08-31 Jonathan Meltzer Officer Other Derivative Acquisition +900 --
2026-08-31 Bryan Vaughn Executive Vice President of Diagnostics Other Derivative Acquisition +1,500 --
2026-08-16 Kerrii Anderson Independent Director Automatic Disposition -3,000 $318.02
2026-08-10 Adam Schechter Chairperson & CEO Automatic Disposition -4,669 $320.37
2026-08-03 Amy Summy Chief Marketing Officer Open Market Disposition -924 $306.74
2026-08-02 Peter Wilkinson Chief Accounting Officer Open Market Disposition -82 $309.22
2026-08-02 Peter Wilkinson Chief Accounting Officer Derivative Exercise and Sale -1,338 $209.25–309.23
2026-07-01 Kathryn Kyle Executive VP, Chief Legal Officer and Corporate Secretary Derivative Exercise and Sale -165 $283.88–286.19
2026-07-01 Kathryn Kyle Executive VP, Chief Legal Officer and Corporate Secretary Intent to Sell (Form 144) -92 $286.19
2026-07-01 Bryan Vaughn Executive Vice President of Diagnostics Derivative Exercise and Sale -327 $283.88–286.19
2026-07-01 Bryan Vaughn Executive Vice President of Diagnostics Intent to Sell (Form 144) -234 $286.19
2026-06-30 Sandra van der Vaart Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Intent to Sell (Form 144) -7,138 $280.48
2026-06-30 Kathryn Kyle Executive VP, Chief Legal Officer and Corporate Secretary Derivative Exercise and Retained +91 --
2026-06-07 Kathryn Kyle Executive VP, Chief Legal Officer and Corporate Secretary Automatic Disposition -762 $263.89
2026-05-10 Adam Schechter Chairperson & CEO Automatic Disposition -5,903 $254.50
2026-05-05 Sandra van der Vaart Executive VP, Chief Legal Officer, Chief Compliance Officer & Corporate Secretary Intent to Sell (Form 144) -6,238 $256.76
2026-03-26 Peter Wilkinson Chief Accounting Officer Automatic Disposition -1,633 $267.05
2026-03-26 Jonathan Meltzer Officer Automatic Disposition -839 $267.05

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 17:21:27 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

莱博科 讨论区 0 条评论

发表评论